Clinical trials
Biliary Tract Diseases clinical trials
Below are recruiting biliary tract diseases clinical trials, each written for real people, not researchers. We’re tracking 119 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06202131Recruiting
Blood test for tumor DNA in gastrointestinal cancers
This trial uses a blood test (ctDNA) to look for genetic material from tumors in patients with gastrointestinal cancers. It may help doctors understand and track your cancer better.
Rome, LazioAges 18–85 - NCT06274879RecruitingPhase 2
Radiofrequency ablation for bile duct cancer
This trial tests a procedure that uses heat (radiofrequency ablation) to treat bile duct cancer that can't be removed by surgery. If you have this type of cancer and are starting standard treatment, this study wants to see if adding this heat treatment is safe and might help.
BernAges 18 years+ - NCT06849193Recruiting
Predicting treatment outcomes in advanced bile duct cancer
This study looks at how well current chemotherapy and immunotherapy work for advanced bile duct or gallbladder cancers that cannot be removed by surgery. Researchers will collect data from multiple centers to build a model that helps predict how patients may respond to treatment.
Nanjing, JiangsuAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT07807956RecruitingPhase 1
Intravenous study drug for advanced solid tumors
This trial tests an investigational drug given through an IV to see if it can help people with advanced solid tumors. It aims to learn about side effects, how the drug works in the body, and whether it can slow or shrink the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT07786766RecruitingPhase 2
Pemigatinib plus immunotherapy for FGFR2-positive bile duct cancer
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
BeijingAges 18–80 - NCT07763301RecruitingPhase 1
Vaccine for advanced liver, bile duct, or pancreatic cancer
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Chengdu, SichuanAges 18–75 - NCT07726446RecruitingPhase 2
Freezing, immunotherapy, and chemo for bile duct tumors
This study tests a new treatment approach for bile duct or gallbladder cancer that has not been treated before. It combines a freezing procedure (cryoablation) with an immunotherapy drug (Relaforp Alpha) and chemotherapy to see if it can shrink tumors or slow disease progression.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06060990Recruiting
Copper and trace elements in biliary tract cancer
This study looks at levels of copper and other minerals in the blood of people with biliary tract cancer (cancer of the bile ducts or gallbladder). If you have not had treatment yet, this trial may help doctors understand how these elements relate to your cancer.
LjubljanaAges 18–80 - NCT07704489Recruiting
Liver and bile duct cancer registry study
This registry collects information from people with liver cancer or bile duct cancer to learn more about the disease and its treatment. Anyone 18 or older with any stage of these cancers can join.
MilanAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07609641Recruiting
Surgery for Bile Duct Cancer: Two Surgical Approaches
This trial compares two different surgical approaches for treating bile duct cancer (cholangiocarcinoma) to see which method works better and is safer. You would undergo surgery and have your recovery and outcomes closely monitored.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07544589RecruitingPhase 1
Study of DISP-10 for advanced gastrointestinal cancers
This trial tests a new treatment called DISP-10 for people with advanced cancers of the digestive system, such as stomach, colon, or bile duct cancers. It aims to see if DISP-10 is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07530354Recruiting
Understanding Body Changes After Bile Duct Surgery in Children
This study follows children who have had bile duct (biliary tract) surgery to understand how their bodies change and adapt afterward. Researchers compare them with healthy children to learn what is normal and help improve care.
Wuhan, HubeiAges Up to 16 years - NCT07433673RecruitingPhase 2
Gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab for locally advanced bile duct cancer
This trial tests a combination of four drugs to see if they shrink locally advanced bile duct or gallbladder cancer that cannot be removed surgically. It is for people who have not had prior treatment for this cancer.
New York, New YorkAges 18 years+ - NCT07398339RecruitingPhase 2
Photodynamic therapy for bile duct cancer
This trial tests a light-activated drug called cosiporfin sodium for people with advanced bile duct cancer that cannot be surgically removed. The treatment targets tumors in the bile ducts and may help shrink them.
Shanghai, Pudong New AreaAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+
Hear when a new Biliary Tract Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract diseases?
- Yes. Clin2 currently lists 119 recruiting biliary tract diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.